Nature Communications (Apr 2021)
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
- Sia Viborg Lindskrog,
- Frederik Prip,
- Philippe Lamy,
- Ann Taber,
- Clarice S. Groeneveld,
- Karin Birkenkamp-Demtröder,
- Jørgen Bjerggaard Jensen,
- Trine Strandgaard,
- Iver Nordentoft,
- Emil Christensen,
- Mateo Sokac,
- Nicolai J. Birkbak,
- Lasse Maretty,
- Gregers G. Hermann,
- Astrid C. Petersen,
- Veronika Weyerer,
- Marc-Oliver Grimm,
- Marcus Horstmann,
- Gottfrid Sjödahl,
- Mattias Höglund,
- Torben Steiniche,
- Karin Mogensen,
- Aurélien de Reyniès,
- Roman Nawroth,
- Brian Jordan,
- Xiaoqi Lin,
- Dejan Dragicevic,
- Douglas G. Ward,
- Anshita Goel,
- Carolyn D. Hurst,
- Jay D. Raman,
- Joshua I. Warrick,
- Ulrika Segersten,
- Danijel Sikic,
- Kim E. M. van Kessel,
- Tobias Maurer,
- Joshua J. Meeks,
- David J. DeGraff,
- Richard T. Bryan,
- Margaret A. Knowles,
- Tatjana Simic,
- Arndt Hartmann,
- Ellen C. Zwarthoff,
- Per-Uno Malmström,
- Núria Malats,
- Francisco X. Real,
- Lars Dyrskjøt
Affiliations
- Sia Viborg Lindskrog
- Department of Molecular Medicine, Aarhus University Hospital
- Frederik Prip
- Department of Molecular Medicine, Aarhus University Hospital
- Philippe Lamy
- Department of Molecular Medicine, Aarhus University Hospital
- Ann Taber
- Department of Molecular Medicine, Aarhus University Hospital
- Clarice S. Groeneveld
- Cartes d’Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer
- Karin Birkenkamp-Demtröder
- Department of Molecular Medicine, Aarhus University Hospital
- Jørgen Bjerggaard Jensen
- Department of Clinical Medicine, Aarhus University
- Trine Strandgaard
- Department of Molecular Medicine, Aarhus University Hospital
- Iver Nordentoft
- Department of Molecular Medicine, Aarhus University Hospital
- Emil Christensen
- Department of Molecular Medicine, Aarhus University Hospital
- Mateo Sokac
- Department of Molecular Medicine, Aarhus University Hospital
- Nicolai J. Birkbak
- Department of Molecular Medicine, Aarhus University Hospital
- Lasse Maretty
- Department of Molecular Medicine, Aarhus University Hospital
- Gregers G. Hermann
- Department of Urology, Herlev hospital, Copenhagen University
- Astrid C. Petersen
- Department of Pathology, Aalborg University Hospital
- Veronika Weyerer
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg
- Marc-Oliver Grimm
- Department of Urology, Jena University Hospital
- Marcus Horstmann
- Department of Urology, Jena University Hospital
- Gottfrid Sjödahl
- Division of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital
- Mattias Höglund
- Division of Oncology and Pathology, Department of Clinical Sciences, Lund University
- Torben Steiniche
- Department of Pathology, Aarhus University Hospital
- Karin Mogensen
- Department of Urology, Herlev hospital, Copenhagen University
- Aurélien de Reyniès
- Cartes d’Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer
- Roman Nawroth
- Department of Urology, Technical University of Munich, Klinikum rechts der Isar
- Brian Jordan
- Departments of Pathology, Urology, Biochemistry and Molecular Genetics, Northwestern University School of Medicine
- Xiaoqi Lin
- Departments of Pathology, Urology, Biochemistry and Molecular Genetics, Northwestern University School of Medicine
- Dejan Dragicevic
- Clinic of Urology, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade
- Douglas G. Ward
- Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham
- Anshita Goel
- Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham
- Carolyn D. Hurst
- Leeds Institute of Medical Research at St James’s, University of Leeds
- Jay D. Raman
- Department of Surgery, Division of Urology, Pennsylvania State University
- Joshua I. Warrick
- Department of Pathology and Laboratory Medicine, Division of Urology, Department of Biochemistry and Molecular Biology, Pennsylvania State University
- Ulrika Segersten
- Department of Surgical Sciences, Uppsala University
- Danijel Sikic
- Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg
- Kim E. M. van Kessel
- Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center
- Tobias Maurer
- Department of Urology, Technical University of Munich, Klinikum rechts der Isar
- Joshua J. Meeks
- Departments of Pathology, Urology, Biochemistry and Molecular Genetics, Northwestern University School of Medicine
- David J. DeGraff
- Department of Pathology and Laboratory Medicine, Division of Urology, Department of Biochemistry and Molecular Biology, Pennsylvania State University
- Richard T. Bryan
- Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham
- Margaret A. Knowles
- Leeds Institute of Medical Research at St James’s, University of Leeds
- Tatjana Simic
- Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade
- Arndt Hartmann
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg
- Ellen C. Zwarthoff
- Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center
- Per-Uno Malmström
- Department of Surgical Sciences, Uppsala University
- Núria Malats
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), CIBERONC
- Francisco X. Real
- Epithelial Carcinogenesis Group, Spanish National Cancer Research Center (CNIO)
- Lars Dyrskjøt
- Department of Molecular Medicine, Aarhus University Hospital
- DOI
- https://doi.org/10.1038/s41467-021-22465-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
Multiple molecular profiling methods are required to study urothelial non-muscle-invasive bladder cancer (NMIBC) due to its heterogeneity. Here the authors integrate multi-omics data of 834 NMIBC patients, identifying a molecular subgroup associated with multiple alterations and worse outcomes.
